Patients are waiting.
We're here to help
innovators get them what they need — faster.
Cell & gene therapies are rewriting the rules of medicine. Behind every novel construct, every viral vector, every dose released to the clinic is a team of people racing against biology, regulation, and time.
GeneFab was built to be the partner that makes that race winnable. Not a vendor that executes from arm's length, but a co-development team that has lived on the innovator side of the table — and brings every learning from every program forward into the next.
We do this because the people developing these therapies are doing the most important work in medicine today. Our job is to remove every operational, technical, and regulatory obstacle between their science and the patients who need it.
Four things our partners say sets us apart — drawn directly from the people who build the programs every day.
You don't hand us a process and wait for results. We map your goals — yield, robustness, CQAs, COGS — and work backwards into a study plan, with you in the room at every gate.
Many of us came from innovator-side companies before joining GeneFab. We know the urgency, the runway pressure, the regulatory calendar — because we've lived it.
Synthetic biology, process development, manufacturing, analytical, and quality — everyone is steps away. Issues that would take a week of inter-vendor email at a bigger CDMO get resolved in an afternoon here.
Most CDMOs are a black box. We share Gantt charts, data packages, and process information in real time — and we're building toward live-batch visibility, so you can see what's happening on our floor without leaving your desk.
We're modality-agnostic by design — built for the cell & gene therapy field's full breadth. Our integrated SynBio research, in-vivo gene therapy expertise, and ex-vivo cell therapy manufacturing meet under one roof.
End-to-end autologous & allogeneic workflows — CAR-T, TCR-T, CAR-NK, Treg, iPSC, and others. Multiple expansion platforms tuned to your modality.
The vehicle is the therapy. We design the construct, engineer cell-specific promoters, and manufacture the lentiviral vector that delivers it — directly to patients, no ex-vivo step required.
The engine for both modalities — lentivirus & gamma-retrovirus production from adherent (2-20 L) to suspension GMP (50-200 L). The same vector platform feeds ex-vivo cell therapy and in-vivo dosing.
Proprietary building blocks for next-gen therapies — cell-specific promoters, kill switches, custom producer cell lines.
Cell & gene therapy is rarely linear. We treat the journey — from genetic design and R&D, through IND-enabling and clinical, to commercial supply — as one continuous platform. Below are the capabilities that platform stitches together, not stops along a conveyor belt.
Process learnings flow backward — manufacturability constraints become design inputs for the next construct, not afterthoughts.
PD scientists, AD analysts, GMP operators, and QC release sit in the same facility. The handshake between stages is a conversation, not a tech package.
Programs evolve from research-scale exploration to commercial-scale supply. We support you across that full arc — minimizing the costly handoffs between vendors, sites, and stages.
At GeneFab, our team aims to get you to the clinic faster — by getting things right the first time, and never being afraid to improve when something can be better.
Quality is driven by GeneFab culture. Every department is responsible for the quality and safety of the product — the product that's taken by the patient.
